Management of hypertension in diabetic patients: outstanding issues

References

• Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358, 580–591 (2008).
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N. Engl. J. Med.342, 905–912 (2000).
   PubMed Web of Science ®Google Scholar
• Abuissa H, Jones PG, Marso SP, O’Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol.46, 821–826 (2005).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension a randomized controlled trial. JAMA292, 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ et al.; British Hypertension Society. Guidelines for management of hypertension report of the fourth working party of the British Hypertension Society, 2004 – BHS IV. J. Hum. Hypertens.18, 139–185 (2004).
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Sowers JR. Hypertension Management in Type 2 diabetes mellitus: recommendations of the Joint National Committee VII. Endocrinol. Metab. Clin. N. Am.34, 63–75 (2005).
   PubMed Web of Science ®Google Scholar
• MCFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab.86, 713–718 (2001).
   PubMed Web of Science ®Google Scholar
• Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am. J. Hypertens.16, 41S–45S (2003).
   Google Scholar
• Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of arterial Hypertension. J. Hypertens.25, 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care34(Suppl. 1), S11–S61 (2010).
   Google Scholar
• Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens.27, 923–934 (2009).
   PubMed Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA276, 1886–1892 (1996).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ317, 703–713 (1998).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA. Antihypertensive treatment with β-blockers and the spectrum of glycaemic control. QJM99, 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med.359, 1565–1576 (2008).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type diabetic patients on albuminuria, retinopathy and strokes. Kidney Int.61, 1086–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and Type 2 diabetes. Circulation107, 753–756 (2003).
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff S, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N. Engl. J. Med.338, 645–652 (1998).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med.340, 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Berthet K, Neal BC, Chalmers JP et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Blood Press.13, 7–13 (2004).
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet370, 829–840 (2007).
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1575–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Kurukulasuriya LR, Sowers JR. Therapies for Type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc. Diabetol.9, 45 (2010).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, Messerli FH. A metaanalysis of 94,492 patients with hypertension treated with β blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol.100, 1254–1262 (2007).
   PubMed Web of Science ®Google Scholar
• Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am. J. Hypertens.16, 381–386 (2003).
   PubMed Web of Science ®Google Scholar
• Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am. Heart J.160, 915–921 (2010).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med.359, 1565–1576 (2008).
   PubMed Web of Science ®Google Scholar